Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Saatci, Ozge, Kaymak, Aysegul, Raza, Umar, Ersan, Pelin G., Akbulut, Ozge, Banister, Carolyn E., Sikirzhytski, Vitali, Tokat, Unal Metin, Aykut, Gamze, Ansari, Suhail A., Dogan, Hayriye Tatli, Dogan, Mehmet, Jandaghi, Pouria, Isik, Aynur, Gundogdu, Fatma, Kosemehmetoglu, Kemal, Dizdar, Omer, Aksoy, Sercan, Akyol, Aytekin, Uner, Aysegul, Buckhaults, Phillip J., Riazalhosseini, Yasser, Sahin, Ozgur
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229173/
https://ncbi.nlm.nih.gov/pubmed/32415208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16199-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados